All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Srividya Swaminathan, The Department of Systems Biology at the Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. We asked, How can natural killer (NK) cells act as reliable predictors and be translated to diagnostics and treatment in ALL?
How can NK cells act as reliable predictors and be translated to diagnostics and treatment in ALL?
Swaminathan reports the results of a study evaluating the phenotypic and functional deficiencies in NK cells of high-risk patients with ALL. Results from this study show that activated NK signature predicts poor clinical prognosis in high-risk patients with ALL.
Inotuzumab ozogamicin effective for the treatment of newly diagnosed older patients and pediatric patients with R/R BCP-ALL – results from two studies
Inotuzumab ozogamicin (InO) is an antibody–drug conjugate composed of an anti-CD22 antibody linked...
Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL
Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two anti-CD19 chimeric antigen receptor (CAR) T-cell...
Subscribe to get the best content related to ALL delivered to your inbox